Pfizer Inc. (PFE)
Earnings Preview: Pfizer (PFE) Q1 Earnings Expected to Decline
Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novo Nordisk vs. Pfizer: Which Healthcare Giant Is the Better Bet?
NVO and PFE clash as the obesity market heats up, with shifting strategies, pipeline bets and growth pressures reshaping their investment outlook.
B. Metzler seel. Sohn & Co. AG Purchases 71,251 Shares of Pfizer Inc. $PFE
B. Metzler seel. Sohn and Co. AG raised its position in Pfizer Inc. (NYSE: PFE) by 12.5% during the undefined quarter, according to its most recent filing with the SEC. The institutional investor owned 639,639 shares of the biopharmaceutical company's stock after acquiring an additional 71,251 shares during the period. B. Metzler seel.
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
The latest trading day saw Pfizer (PFE) settling at $26.8, representing a -1.87% change from its previous close.
Pfizer Could Surprise Again This Earnings Season (Preview)
Pfizer continues delivering consistent earnings beats, driven by cost-cutting initiatives and improving margins as lower-margin COVID products fade from its overall revenue mix. The company's pipeline remains robust, with multiple Phase 3 programs and obesity initiatives that could drive long-term growth and offset upcoming patent expirations. Upcoming earnings may exceed expectations again, as analysts remain cautious despite Pfizer's strong track record of outperforming consensus estimates in recent quarters.
Pfizer GLP-1 weight loss drug available for pre-order in China
Pfizer's GLP-1 weight management treatment Xianweiying is available for pre-order in China, a Reuters check on a local e-commerce platform showed, ramping up competition with rivals in a market analysts expect to be worth billions of dollars.
Pfizer's Strategy and Innovation Officer Andrew Baum to leave drugmaker, analyst note says
Pfizer's Chief Strategy and Innovation Officer, Andrew Baum, is transitioning to a new role and will eventually leave the company as part of the U.S. drugmaker's strategic simplification, according to an analyst note on Monday.
Pfizer's Non-Oncology Portfolio in Focus Ahead of Q1 Earnings
Pfizer PFE is scheduled to report its first-quarter 2026 results on May 5, with investor focus firmly on its oncology portfolio, which contributes roughly 27% of total revenues. Leading cancer therapies in its lineup include Ibrance, Xtandi, Lorbrena, Braftovi/Mektovi, as well as antibody-drug conjugates like Padcev acquired through Seagen.
Pfizer (PFE) Outperforms Broader Market: What You Need to Know
Pfizer (PFE) reached $27.34 at the closing of the latest trading day, reflecting a +1.56% change compared to its last close.
Trellus Health shares jump 39% on Pfizer deal renewal
Trellus Health PLC (AIM:TRLS), the digital chronic disease management platform, surged 39% to 0.28p after the company announced it had renewed its licensing agreement with Pfizer. Under the renewed deal, Pfizer will continue to license Trellus Health's patient-support educational content for use in its inflammatory bowel disease (IBD) digital application.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
How Pfizer's Oncology Portfolio Is Shaping Up Before Q1 Results
Pfizer PFE is one of the largest and most successful drugmakers in oncology with an established presence in breast, genitourinary, thoracic, gastrointestinal cancer and blood cancers. It boasts a strong portfolio of approved cancer medicines as well as a robust pipeline of cancer candidates with a focus on multiple modalities, including small molecules, antibody-drug conjugates (ADCs) and immuno-oncology biologics.
